{"id":"https://openalex.org/W2905070646","doi":"https://doi.org/10.1038/s41467-018-07551-w","title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","display_name":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","alternate_titles":[],"publication_year":2018,"publication_date":"2018-12-17","ids":{"openalex":"https://openalex.org/W2905070646","doi":"https://doi.org/10.1038/s41467-018-07551-w","mag":"2905070646","pmid":"https://pubmed.ncbi.nlm.nih.gov/30559424","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6297231"},"language":"en","primary_location":{"id":"doi:10.1038/s41467-018-07551-w","doi":"https://doi.org/10.1038/s41467-018-07551-w","is_oa":true,"landing_page_url":"https://doi.org/10.1038/s41467-018-07551-w","pdf_url":"https://www.nature.com/articles/s41467-018-07551-w.pdf","source":{"id":"https://openalex.org/S64187185","display_name":"Nature Communications","issn_l":"2041-1723","issn":["2041-1723"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","oarl","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nature Communications","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2905070646"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.nature.com/articles/s41467-018-07551-w.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008297969","display_name":"Adriana E. Tron","orcid":"https://orcid.org/0000-0001-9506-2121","observed_orcids":["https://orcid.org/0000-0001-9506-2121"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Adriana E. Tron","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028981261","display_name":"Matthew A. Belmonte","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Matthew A. Belmonte","raw_affiliation_strings":["LifeMine Therapeutics, Cambridge, MA, USA","Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LifeMine Therapeutics, Cambridge, MA, USA","institution_ids":[]},{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024517878","display_name":"Ammar Adam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ammar Adam","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","Surface Oncology, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"Surface Oncology, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049852492","display_name":"Brian M. Aquila","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210116259","display_name":"Alkermes (United States)","ror":"https://ror.org/038hqfn26","country_code":"US","type":"company","lineage":["https://openalex.org/I1328445063","https://openalex.org/I4210116259"]},{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Brian M. Aquila","raw_affiliation_strings":["Alkermes, Inc., Waltham, MA, USA","Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alkermes, Inc., Waltham, MA, USA","institution_ids":["https://openalex.org/I4210116259"]},{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016626239","display_name":"Lawrence Boise","orcid":"https://orcid.org/0000-0001-9436-8815","observed_orcids":["https://orcid.org/0000-0001-9436-8815"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lawrence H. Boise","raw_affiliation_strings":["Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA","Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA","institution_ids":["https://openalex.org/I150468666"]},{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052633808","display_name":"Elisabetta Chiarparin","orcid":"https://orcid.org/0000-0002-2998-1346","observed_orcids":["https://orcid.org/0000-0002-2998-1346"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Elisabetta Chiarparin","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043764611","display_name":"Justin R. Cidado","orcid":"https://orcid.org/0000-0003-1748-4438","observed_orcids":["https://orcid.org/0000-0003-1748-4438"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Justin Cidado","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036255361","display_name":"Kevin J. Embrey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kevin J. Embrey","raw_affiliation_strings":["Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000833013","display_name":"Eric T. Gangl","orcid":"https://orcid.org/0000-0001-5243-2524","observed_orcids":["https://orcid.org/0000-0001-5243-2524"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eric Gangl","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065542161","display_name":"Francis D. Gibbons","orcid":"https://orcid.org/0000-0003-1606-1740","observed_orcids":["https://orcid.org/0000-0003-1606-1740"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Francis D. Gibbons","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057423528","display_name":"Gareth Peter Gregory","orcid":"https://orcid.org/0000-0002-4170-0682","observed_orcids":["https://orcid.org/0000-0002-4170-0682"]},"institutions":[{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]},{"id":"https://openalex.org/I4210121067","display_name":"Monash Health","ror":"https://ror.org/02t1bej08","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210121067"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gareth P. Gregory","raw_affiliation_strings":["Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia","School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, 3800, Australia"],"raw_orcid":"https://orcid.org/0000-0002-4170-0682","affiliations":[{"raw_affiliation_string":"Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia","institution_ids":["https://openalex.org/I2800555584"]},{"raw_affiliation_string":"School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, 3800, Australia","institution_ids":["https://openalex.org/I4210121067","https://openalex.org/I56590836"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043016182","display_name":"David Hargreaves","orcid":"https://orcid.org/0000-0003-4441-0039","observed_orcids":["https://orcid.org/0000-0003-4441-0039"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"David Hargreaves","raw_affiliation_strings":["Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056448870","display_name":"J. Adam Hendricks","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Adam Hendricks","raw_affiliation_strings":["Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036732655","display_name":"Jeffrey W. Johannes","orcid":"https://orcid.org/0000-0001-7242-6682","observed_orcids":["https://orcid.org/0000-0001-7242-6682"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jeffrey W. Johannes","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":"https://orcid.org/0000-0001-7242-6682","affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052829828","display_name":"Ricky W. Johnstone","orcid":"https://orcid.org/0000-0001-7053-9237","observed_orcids":["https://orcid.org/0000-0001-7053-9237"]},"institutions":[{"id":"https://openalex.org/I165779595","display_name":"The University of Melbourne","ror":"https://ror.org/01ej9dk98","country_code":"AU","type":"education","lineage":["https://openalex.org/I165779595"]},{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ricky W. Johnstone","raw_affiliation_strings":["Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia","The Sir Peter MacCallum Center, Department of Oncology, University of Melbourne, Parkville, VIC, 3000, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia","institution_ids":["https://openalex.org/I2800555584"]},{"raw_affiliation_string":"The Sir Peter MacCallum Center, Department of Oncology, University of Melbourne, Parkville, VIC, 3000, Australia","institution_ids":["https://openalex.org/I165779595","https://openalex.org/I2800555584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016781397","display_name":"Steven L. Kazmirski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094323","display_name":"Fulcrum Therapeutics (United States)","ror":"https://ror.org/006f8jv23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094323"]},{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Steven L. Kazmirski","raw_affiliation_strings":["Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","Fulcrum Therapeutics, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"Fulcrum Therapeutics, Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210094323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033169967","display_name":"Jason G. Kettle","orcid":"https://orcid.org/0000-0001-7373-0758","observed_orcids":["https://orcid.org/0000-0001-7373-0758"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jason G. Kettle","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083435506","display_name":"Michelle L. Lamb","orcid":"https://orcid.org/0000-0002-3005-8065","observed_orcids":["https://orcid.org/0000-0002-3005-8065"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michelle L. Lamb","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":"https://orcid.org/0000-0002-3005-8065","affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066865482","display_name":"Shannon M. Matulis","orcid":"https://orcid.org/0009-0009-4223-2006","observed_orcids":["https://orcid.org/0009-0009-4223-2006"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Shannon M. Matulis","raw_affiliation_strings":["Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA","Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA","institution_ids":["https://openalex.org/I150468666"]},{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022520524","display_name":"Ajay K. Nooka","orcid":"https://orcid.org/0000-0003-4165-6869","observed_orcids":["https://orcid.org/0000-0003-4165-6869"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ajay K. Nooka","raw_affiliation_strings":["Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA","Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA","institution_ids":["https://openalex.org/I150468666"]},{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Martin J. Packer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Martin J. Packer","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Alderley Park, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Alderley Park, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100772367","display_name":"Bo Peng","orcid":"https://orcid.org/0000-0003-4183-5939","observed_orcids":["https://orcid.org/0000-0003-4183-5939","https://orcid.org/0009-0002-3434-1885","https://orcid.org/0000-0003-0457-3159"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bo Peng","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053808561","display_name":"Philip B. Rawlins","orcid":"https://orcid.org/0000-0002-1595-5550","observed_orcids":["https://orcid.org/0000-0002-1595-5550"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Philip B. Rawlins","raw_affiliation_strings":["Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035158211","display_name":"DANIEL W. ROBBINS","orcid":"https://orcid.org/0009-0006-7953-5447","observed_orcids":["https://orcid.org/0009-0006-7953-5447","https://orcid.org/0009-0007-1631-3238"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]},{"id":"https://openalex.org/I4210158736","display_name":"Nurix (United States)","ror":"https://ror.org/05k879m03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158736"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Daniel W. Robbins","raw_affiliation_strings":["Nurix, Inc., San Francisco, CA, USA","Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nurix, Inc., San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210158736"]},{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003340825","display_name":"Alwin G. Schuller","orcid":"https://orcid.org/0000-0001-9163-5885","observed_orcids":["https://orcid.org/0000-0001-9163-5885"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alwin G. Schuller","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059318507","display_name":"Nancy Su","orcid":"https://orcid.org/0009-0006-3168-7011","observed_orcids":["https://orcid.org/0009-0006-3168-7011"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nancy Su","raw_affiliation_strings":["Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078659370","display_name":"Wenzhan Yang","orcid":"https://orcid.org/0000-0002-4591-5007","observed_orcids":["https://orcid.org/0000-0002-4591-5007"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Wenzhan Yang","raw_affiliation_strings":["Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":"https://orcid.org/0000-0002-4591-5007","affiliations":[{"raw_affiliation_string":"Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Qing Ye","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Qing Ye","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109203504","display_name":"Xiaolan Zheng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Xiaolan Zheng","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052418709","display_name":"John Paul Secrist","orcid":"https://orcid.org/0000-0003-0447-6295","observed_orcids":["https://orcid.org/0000-0003-0447-6295"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Paul Secrist","raw_affiliation_strings":["LifeMine Therapeutics, Cambridge, MA, USA","Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LifeMine Therapeutics, Cambridge, MA, USA","institution_ids":[]},{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041785188","display_name":"Edwin A. Clark","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Edwin A. Clark","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026285477","display_name":"David M. Wilson","orcid":"https://orcid.org/0000-0002-1095-046X","observed_orcids":["https://orcid.org/0000-0002-1095-046X"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"David M. Wilson","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091683932","display_name":"Stephen E. Fawell","orcid":"https://orcid.org/0000-0002-1962-891X","observed_orcids":["https://orcid.org/0000-0002-1962-891X"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stephen E. Fawell","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070605323","display_name":"Alexander W. Hird","orcid":"https://orcid.org/0000-0002-2699-7449","observed_orcids":["https://orcid.org/0000-0002-2699-7449"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Alexander W. Hird","raw_affiliation_strings":["Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA. alexander.hird@astrazeneca.com","Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA"],"raw_orcid":"https://orcid.org/0000-0002-2699-7449","affiliations":[{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA. alexander.hird@astrazeneca.com","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA","institution_ids":["https://openalex.org/I4210150756"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":11,"corresponding_author_ids":["https://openalex.org/A5070605323"],"corresponding_institution_ids":["https://openalex.org/I4210150756"],"apc_list":{"value":6990,"currency":"USD","value_usd":6990},"apc_paid":{"value":6990,"currency":"USD","value_usd":6990},"fwci":16.5209,"has_fulltext":true,"cited_by_count":537,"citation_normalized_percentile":{"value":0.99665894,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"9","issue":"1","first_page":"5341","last_page":"5341"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mcl-1","display_name":"Mcl-1","score":0.8389999866485596},{"id":"https://openalex.org/keywords/azd5991","display_name":"AZD5991","score":0.996999979019165},{"id":"https://openalex.org/keywords/mcl-1-inhibitors","display_name":"Mcl-1 inhibitors","score":0.8830000162124634},{"id":"https://openalex.org/keywords/bcl-2-family-proteins","display_name":"Bcl-2 family proteins","score":0.9229999780654907},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.843999981880188},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.8700000047683716},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":1.0},{"id":"https://openalex.org/keywords/mitochondrial-apoptosis","display_name":"mitochondrial apoptosis","score":0.9300000071525574},{"id":"https://openalex.org/keywords/macrocycles","display_name":"macrocycles","score":0.7160000205039978},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.8399999737739563},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9980000257492065},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.8209999799728394},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8510000109672546}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.8538888692855835},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.7894502878189087},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.789391815662384},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6494718194007874},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.6228122711181641},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.5714886784553528},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.524981677532196},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5131245255470276},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.5010621547698975},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4822138547897339},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.44808143377304077},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3634988069534302},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3088870942592621},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.3023633360862732},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2987082898616791},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.16693994402885437},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.05585160851478577},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008810","descriptor_name":"Mice, Inbred C57BL","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011923","descriptor_name":"Rats, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D016513","descriptor_name":"Mice, SCID","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D018360","descriptor_name":"Crystallography, X-Ray","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019086","descriptor_name":"Bridged Bicyclo Compounds, Heterocyclic","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064549","descriptor_name":"Myeloid Cell Leukemia Sequence 1 Protein","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D064549","descriptor_name":"Myeloid Cell Leukemia Sequence 1 Protein","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":9,"locations":[{"id":"doi:10.1038/s41467-018-07551-w","doi":"https://doi.org/10.1038/s41467-018-07551-w","is_oa":true,"landing_page_url":"https://doi.org/10.1038/s41467-018-07551-w","pdf_url":"https://www.nature.com/articles/s41467-018-07551-w.pdf","source":{"id":"https://openalex.org/S64187185","display_name":"Nature Communications","issn_l":"2041-1723","issn":["2041-1723"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","oarl","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nature Communications","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5269311","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6297231","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6297231","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6297231/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nat Commun","raw_type":"Text"},{"id":"pmh:oai:monash.edu:openaire/78f8bf4f-cda1-4019-9aa8-a6db7cddd4a4","doi":null,"is_oa":true,"landing_page_url":"https://research.monash.edu/en/publications/78f8bf4f-cda1-4019-9aa8-a6db7cddd4a4","pdf_url":null,"source":{"id":"https://openalex.org/S4306402625","display_name":"Monash University Research Portal (Monash University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I56590836","host_organization_name":"Monash University","host_organization_lineage":["https://openalex.org/I56590836"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},{"id":"pmid:30559424","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30559424","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nature communications","raw_type":"Journal Article"},{"id":"pmh:oai:RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-07551-w","doi":null,"is_oa":false,"landing_page_url":"https://www.nature.com/articles/s41467-018-07551-w","pdf_url":null,"source":{"id":"https://openalex.org/S4306401271","display_name":"RePEc: Research Papers in Economics","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I77793887","host_organization_name":"Federal Reserve Bank of St. Louis","host_organization_lineage":["https://openalex.org/I77793887"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article"},{"id":"pmh:oai:doaj.org/article:45f79aa080d64d0eba421e64eb8be4ff","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/45f79aa080d64d0eba421e64eb8be4ff","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)","raw_type":"article"},{"id":"pmh:oai:doaj.org/article:814ff3ef6b204d84917e2b025f3e1da9","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/814ff3ef6b204d84917e2b025f3e1da9","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)","raw_type":"article"},{"id":"pmh:oai:jupiter.its.unimelb.edu.au:11343/253625","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/11343/253625","pdf_url":null,"source":{"id":"https://openalex.org/S4377196259","display_name":"Minerva Access (University of Melbourne)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I165779595","host_organization_name":"The University of Melbourne","host_organization_lineage":["https://openalex.org/I165779595"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1038/s41467-018-07551-w","doi":"https://doi.org/10.1038/s41467-018-07551-w","is_oa":true,"landing_page_url":"https://doi.org/10.1038/s41467-018-07551-w","pdf_url":"https://www.nature.com/articles/s41467-018-07551-w.pdf","source":{"id":"https://openalex.org/S64187185","display_name":"Nature Communications","issn_l":"2041-1723","issn":["2041-1723"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","oarl","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nature Communications","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2905070646.pdf","grobid_xml":"https://content.openalex.org/works/W2905070646.grobid-xml"},"referenced_works_count":46,"referenced_works":["https://openalex.org/W1969232124","https://openalex.org/W1981466043","https://openalex.org/W1982254984","https://openalex.org/W1983470364","https://openalex.org/W1988377311","https://openalex.org/W1990593744","https://openalex.org/W1990983360","https://openalex.org/W1993251792","https://openalex.org/W2003765708","https://openalex.org/W2009486785","https://openalex.org/W2014767087","https://openalex.org/W2016661249","https://openalex.org/W2018902131","https://openalex.org/W2048217074","https://openalex.org/W2050702798","https://openalex.org/W2056641238","https://openalex.org/W2059416155","https://openalex.org/W2066404900","https://openalex.org/W2069002336","https://openalex.org/W2083470652","https://openalex.org/W2086546153","https://openalex.org/W2091562724","https://openalex.org/W2098629192","https://openalex.org/W2117692326","https://openalex.org/W2158414356","https://openalex.org/W2160075057","https://openalex.org/W2171224722","https://openalex.org/W2192121806","https://openalex.org/W2278828177","https://openalex.org/W2326290971","https://openalex.org/W2338674998","https://openalex.org/W2471089142","https://openalex.org/W2485824342","https://openalex.org/W2510710599","https://openalex.org/W2511071867","https://openalex.org/W2517282085","https://openalex.org/W2534349779","https://openalex.org/W2566864171","https://openalex.org/W2582696216","https://openalex.org/W2739786760","https://openalex.org/W2749566554","https://openalex.org/W2766623255","https://openalex.org/W2771897018","https://openalex.org/W2773114573","https://openalex.org/W2884332433","https://openalex.org/W7097643049"],"related_works":["https://openalex.org/W2887146895","https://openalex.org/W2729701087","https://openalex.org/W2902184543","https://openalex.org/W3208066676","https://openalex.org/W2903132660","https://openalex.org/W4385740086","https://openalex.org/W4290759415","https://openalex.org/W3006985196","https://openalex.org/W3091174927","https://openalex.org/W2902413705"],"abstract_inverted_index":{"Mcl-1":[0,25,37,57,70],"is":[1],"a":[2,46,114,132],"member":[3],"of":[4,8,17,24,36,106,142],"the":[5,34,87],"Bcl-2":[6],"family":[7],"proteins":[9],"that":[10,65],"promotes":[11],"cell":[12],"survival":[13],"by":[14,85],"preventing":[15],"induction":[16],"apoptosis":[18,74],"in":[19,59,75,97,103,121,144],"many":[20],"cancers.":[21],"High":[22],"expression":[23],"causes":[26],"tumorigenesis":[27],"and":[28,54,71,81,109],"resistance":[29],"to":[30,69],"anticancer":[31,40],"therapies":[32],"highlighting":[33],"potential":[35],"inhibitors":[38],"as":[39,118],"drugs.":[41],"Here,":[42],"we":[43],"describe":[44],"AZD5991,":[45],"rationally":[47],"designed":[48],"macrocyclic":[49],"molecule":[50],"with":[51,99,123,146],"high":[52],"selectivity":[53],"affinity":[55],"for":[56,140],"currently":[58],"clinical":[60,135],"development.":[61],"Our":[62],"studies":[63],"demonstrate":[64],"AZD5991":[66,92,143],"binds":[67],"directly":[68],"induces":[72],"rapid":[73],"cancer":[76],"cells,":[77],"most":[78],"notably":[79],"myeloma":[80,108],"acute":[82,110],"myeloid":[83,111],"leukemia,":[84],"activating":[86],"Bak-dependent":[88],"mitochondrial":[89],"apoptotic":[90],"pathway.":[91],"shows":[93],"potent":[94],"antitumor":[95],"activity":[96],"vivo":[98],"complete":[100],"tumor":[101],"regression":[102],"several":[104],"models":[105],"multiple":[107],"leukemia":[112],"after":[113],"single":[115],"tolerated":[116],"dose":[117],"monotherapy":[119],"or":[120,125],"combination":[122],"bortezomib":[124],"venetoclax.":[126],"Based":[127],"on":[128],"these":[129],"promising":[130],"data,":[131],"Phase":[133],"I":[134],"trial":[136],"has":[137],"been":[138],"launched":[139],"evaluation":[141],"patients":[145],"hematological":[147],"malignancies":[148],"(NCT03218683).":[149]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2905070646","counts_by_year":[{"year":2026,"cited_by_count":32},{"year":2025,"cited_by_count":59},{"year":2024,"cited_by_count":64},{"year":2023,"cited_by_count":67},{"year":2022,"cited_by_count":79},{"year":2021,"cited_by_count":94},{"year":2020,"cited_by_count":88},{"year":2019,"cited_by_count":49},{"year":2018,"cited_by_count":3}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2018-12-22T00:00:00"}
